Literature DB >> 23288469

The effects of active metabolites on parameter estimation in linear mixed effect models of concentration-QT analyses.

Peter L Bonate1.   

Abstract

Monte Carlo simulation was used to assess the performance of linear mixed effect models (LMEMs) to characterize the concentration-effect relationship when both parent and metabolite concentrations were available. Parent and metabolite concentrations were simulated under an experimental design that mimicked a thorough QT study. Simulations were done where both parent and metabolite concentration prolonged double-delta time-matched placebo controlled QTc (ddQTc) intervals. LMEMs were then estimated where parent and metabolite concentrations, parent concentrations alone, or metabolite concentrations alone were used as the independent variables. The relative error in the estimation of the parent and metabolite slope compared to known theoretical values was calculated. Additional simulations were done comparing the estimate of the one-sided upper 95% confidence interval at 1 time unit post-dose in an under- and overfit model compared to the true data generating model. When both parent and metabolite were included in the LMEM and both parent and metabolite prolonged ddQTc intervals, despite some high correlations between parent and metabolite concentrations, under all conditions the parent slope parameter θ(p) was estimated with good accuracy, having a mean relative error within ±20% of the true value, whereas estimation of the metabolite slope θ(m) was overpredicted with bias increasing as the ratio of the metabolite elimination rate constant (K(elm)) to metabolite formation rate constant (K(f)) increased. Variability in θ(m) relative error increased as the metabolite potency decreased. Metabolite ratio had no effect on the ability to estimate the parent or metabolite slope. When only parent or metabolite concentration was used as the independent variable in a LMEM and both parent and metabolite concentrations prolonged ddQTc intervals, severe omitted variable bias resulted. When estimating the one-sided upper 95% confidence interval, underfitted models tended to have higher predicted values which would suggest that an underfitted model would be more likely to declare a "QT effect", whereas an overfitted model resulted in little difference compared to the true model. When time-matched parent and metabolite concentrations are available, both parent and metabolite concentrations should be included in the model simultaneously recognizing that the estimation of the metabolite slope may be biased under certain conditions. It is better to have an overfitted model than an underfitted model, although model simplification through removal of nonsignificant model terms in an overfitted model should not be neglected. Including both parent and metabolite concentrations in a model, even when the metabolite does not affect ddQTc intervals, does not tend to result in biased parameter estimates and in most cases will not result in inflated confidence intervals for predicted values, e.g., around maximal concentrations at the therapeutic dose. It is recommended that when time-matched parent and metabolite concentrations are available, parent and metabolite concentrations not be analyzed separately because either one or the other will result in biased parameter estimates and inflated point estimates and confidence intervals for predicted values.

Mesh:

Substances:

Year:  2013        PMID: 23288469     DOI: 10.1007/s10928-012-9292-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  9 in total

1.  The effect of collinearity on parameter estimates in nonlinear mixed effect models.

Authors:  P L Bonate
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

3.  Considerations for clinical trial design and data analyses of thorough QT studies using drug-drug interaction.

Authors:  Hao Zhu; Yaning Wang; Jogarao V Gobburu; Christine E Garnett
Journal:  J Clin Pharmacol       Date:  2010-05-10       Impact factor: 3.126

4.  Thorough QT study with recommended and supratherapeutic doses of tolterodine.

Authors:  B K Malhotra; P Glue; K Sweeney; R Anziano; J Mancuso; P Wicker
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

Review 5.  Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

Authors:  Christine E Garnett; Nhi Beasley; V Atul Bhattaram; Pravin R Jadhav; Rajanikanth Madabushi; Norman Stockbridge; Christoffer W Tornøe; Yaning Wang; Hao Zhu; Jogarao V Gobburu
Journal:  J Clin Pharmacol       Date:  2008-01       Impact factor: 3.126

6.  A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.

Authors:  Robert S Mansbach; Elizabeth Ludington; Roberta Rogowski; Jeffrey P Kittrelle; Philip Jochelson
Journal:  Clin Ther       Date:  2011-07-01       Impact factor: 3.393

7.  Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.

Authors:  J Shi; T M Ludden; A P Melikian; M R Gastonguay; P H Hinderling
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

8.  Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.

Authors:  Dan Chen; Ritu Lal; Katie Zomorodi; Harisha Atluri; Judy Ho; Wendy Luo; James Tovera; Daniel Bonzo; Kenneth Cundy
Journal:  Clin Ther       Date:  2012-02       Impact factor: 3.393

9.  Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study.

Authors:  Glenn F Carlson; Conrad K P Tou; Shamik Parikh; Bruce K Birmingham; Kathleen Butler
Journal:  Diabetes Ther       Date:  2011-06-24       Impact factor: 2.945

  9 in total
  5 in total

1.  Estimation of QT interval prolongation through model-averaging.

Authors:  Peter L Bonate
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-18       Impact factor: 2.745

Review 2.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

Review 3.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

4.  Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.

Authors:  Emily Briggs; Sunny Chapel; Peijin Zhang; Maria Palmisano; Jonathan Q Tran
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-01-05

5.  Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia.

Authors:  Dongwoo Kang; Elizabeth Ludwig; David Jaworowicz; Hannah Huang; Jill Fiedler-Kelly; Jorge Cortes; Siddhartha Ganguly; Samer Khaled; Alwin Krämer; Mark Levis; Giovanni Martinelli; Alexander Perl; Nigel Russell; Malaz Abutarif; Youngsook Choi; Ophelia Yin
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-08       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.